Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Selma TobudicChristina ForstnerHeinz BurgmannHeimo LaglerChristoph SteiningerLudwig TrabyMathias G VossenStefan WinklerFlorian ThalhammerPublished in: Infection (2019)
We demonstrated high clinical effectiveness of dalbavancin for acute gram-positive infections primarily acute SSTI, acute septic arthritis, acute osteomyelitis and spondylodiscitis. In patients with biofilm-associated infection (chronic infection or joint prosthesis), source control was absolutely necessary for treatment success.
Keyphrases
- liver failure
- respiratory failure
- soft tissue
- drug induced
- aortic dissection
- randomized controlled trial
- rheumatoid arthritis
- systematic review
- gram negative
- staphylococcus aureus
- escherichia coli
- stem cells
- bone mineral density
- mesenchymal stem cells
- body composition
- bone marrow
- cystic fibrosis
- wound healing
- replacement therapy